The relationship between antibiotic therapy in early childhood and the symptoms of allergy in children aged 6-8 years – the questionnaire study results.

Related Articles

The relationship between antibiotic therapy in early childhood and the symptoms of allergy in children aged 6-8 years – the questionnaire study results.

Int J Occup Med Environ Health. 2012 Dec 3;

Authors: Raciborski F, Tomaszewska A, Komorowski J, Samel-Kowalik P, Bia?oszewski AZ, Artur W, Lusawa A, Szyma?ski J, Opoczy?ska D, Dru?ba M, Borowicz J, Lipiec A, Kapalczynski WJ, Samoli?ski B

Abstract
INTRODUCTION: Studies based on the ISAAC questionnaire suggest a correlation between the use of antibiotics and the prevalence of asthma and allergy in children aged 6-7 years. The number of courses of antibiotic therapy is an important factor. OBJECTIVES: To investigate the relationship between the use of antibiotics during the first years of life and the prevalence of allergy and asthma among children (aged 6-8 years) in the urban population of Poland. MATERIALS AND METHODS: A survey-based study with a self-completed questionnaire. The respondents were parents of children aged 6-8 years living in Warszawa, Poland. 1461 completed questionnaires were collected. RESULTS: Asthma was declared in 4.3% of the children. Wheezing and/or sibilant rhonchi within 12 months before the study was observed in 13.5% of the cases. Asthma medication was taken by 21.8% of the children. Allergic rhinitis was declared in 18.7% of the children. Problems with sneezing, rhinorrhea, and nasal congestion not associated with cold or fever were observed in 40.7% of the children. The analysis of the odds ratios between the use of antibiotics and the symptoms of allergic diseases revealed a clear correlation. The highest odds ratio was observed between the completion of over three courses of antibiotic therapy prior to the age of 12 months and the declaration of one of the following: asthma (OR = 5.59, 95% CI: 2.6-12.01), wheezing and/or sibilant rhonchi (OR = 4.68, 95% CI: 3.01-7.27) and taking medicines for breathlessness (OR = 5.12, 95% CI: 3.42-7.68). CONCLUSIONS: There is a direct relationship between antibiotic use in the first 3 years of life and asthma and allergy symptoms in children aged 6-8 years old.

PMID: 23212289 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

MediciNova Reports Third Quarter 2012 Results and Update on MN-221 … – NASDAQ

MediciNova Reports Third Quarter 2012 Results and Update on MN-221
NASDAQ
The decrease in research and development expenses was mainly due to a decrease in spending on MN-221 due to the completion of the MN-221-CL-007 trial in patients with acute exacerbations of asthma, partially offset by an increase in spending on our
MediciNova Says Considering Cost, Timing and Design of Future Trials; FDA Benzinga

all 8 news articles »

View full post on asthma – Google News

Synairgen in Drug Partnership Talks After Study Results – Businessweek

Synairgen in Drug Partnership Talks After Study Results
Businessweek
Synairgen Plc (SNG) is in talks with potential partners following the results of a study of an experimental medicine targeting infections that trigger asthma attacks, Chief Executive Officer Richard Marsden said. Synairgen is speaking with larger
New drug 'stops common cold asthma deaths'Hayling Islander

all 3 news articles »

View full post on asthma – Google News

MediciNova Announces Positive Preliminary Results From a Multi-Day, Repeat … – NASDAQ

MediciNova Announces Positive Preliminary Results From a Multi-Day, Repeat
NASDAQ
"There is a significant unmet medical need for an IV agent like MN-221 for asthma and COPD patients who are admitted to the ER due to a severe episode that is unresponsive to standard therapy," said Kazuko Matsuda, M.D., Ph.D., M.P.H, Chief Medical

and more »

View full post on asthma – Google News

MediciNova Reports Results of a Phase 2b Clinical Trial of MN-221 in Asthma … – FierceBiotech

MediciNova Reports Results of a Phase 2b Clinical Trial of MN-221 in Asthma
FierceBiotech
MediciNova intends to design pivotal trial(s) that will include technological and operational improvements and further controls for medications that are not typically used in the treatment of acute exacerbations of asthma and were over-represented in
MediciNova Reports Results Of A Phase 2b Trial Of MN-221 In Asthma ExacerbationsNASDAQ

all 28 news articles »

View full post on asthma – Google News